Optic neuritis: A review

International MS Journal

Volumn 16, Issue 3, 2009, Pages 82-89

  Shams, P N ^a,b   Plant, Gordon T ^a,b,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Corticosteroids; Demyelinating optic neuropathy; Disease modifying drugs; Multiple sclerosis; Optic neuritis; Optic neuritis treatment trial

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PLACEBO; PREDNISOLONE; PREDNISONE; ANTIRHEUMATIC AGENT; IMMUNOLOGICAL ADJUVANT;

BONE NECROSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COLOR VISION DEFECT; DEMYELINATION; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MEGADOSE; ETHNIC DIFFERENCE; EYE PAIN; HUMAN; INSOMNIA; MOOD DISORDER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PANCREATITIS; PATHOGENESIS; PREVALENCE; PROGNOSIS; RECURRENCE RISK; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; VISUAL IMPAIRMENT; WEIGHT GAIN; BRAIN; DISEASE COURSE; DRUG EFFECT; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VISION TEST;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; BRAIN; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OPTIC NEURITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISION TESTS;

EID: 73349093440     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Beck RW, Trobe JD, Moke PS et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121: 944-949.
2. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008; 115: 1079-1082.
3. Cleary PA, Beck RW, Anderson MM et al. Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials 1993; 14: 123-142.
4. Kidd DP: Inflammatory optic neuropathies not associated with multiple sclerosis. In: Neuroophthalmology (Kidd DP, Newman NJ, Biousse V, eds). Boston: Butterworth Heinemann 2008; pp153-190.
5. Kidd DP, Plant GT. Optic neuritis. In: Neuro-ophthalmology (Kidd DP, Newman NJ, Biousse V, eds). Boston: Butterworth Heinemann 2008; pp134-152.
6. Plant GT. Optic neuritis and multiple sclerosis. Curr Opin Neurol 2008; 21: 16-21.
7. Beck RW, Gal RL, Bhatti MT et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004; 137: 77-83.
8. Costello F, Coupland S, Hodge W et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59: 963-969.
9. Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006; 113: 324-332.
10. Trip SA, Schlottmann PG, Jones SJ et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005; 58: 383-391.
11. Henderson AP, Trip SA, Schlottmann PG et al. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain 2008; 131: 277-287.
12. Kurtzke JF. Optic neuritis or multiple sclerosis. Arch Neurol 1985; 42: 704-710.
13. Rodriguez M, Siva A, Cross SA et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995; 45: 244-250.
14. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55: 186-192.
15. Kurtzke JF. Multiple sclerosis among immigrants. Br Med J 1976; 1: 1527-1528.
16. Dean G, Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 565-568.
17. Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354: 1273-1280.
18. Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol 2003; 18: 174-180.
19. Brady KM, Brar AS, Lee AG et al. Optic neuritis in children: clinical features and visual outcome. J AAPOS 1999; 3: 98-103.
20. Morales DS, Siatkowski RM, Howard CW et al. Optic neuritis in children. J Pediatr Ophthalmol Strabismus 2000; 37: 254-259.
21. Lucchinetti CF, Kiers L, O'Duffy A et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49: 1413-1418.
22. Schneck ME, Haegerstrom-Portnoy G. Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 1997; 38: 2278-2289.
23. Goldstein JE, Cogan DG. Exercise and the optic neuropathy of multiple sclerosis. Arch Ophthalmol 1964; 72: 168-170.
24. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991; 109: 1673-1678.
25. Beck RW, Cleary PA, Anderson MM Jr et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581-588.
26. Hickman SJ, Ko M, Chaudhry F et al. Optic neuritis: An update typical and atypical optic neuritis. Neuroophthalmology 2008; 32: 237-248.
27. Hickman SJ, Dalton CM, Miller DH et al. Management of acute optic neuritis. Lancet 2002; 360: 1953-1962.
28. Brass SD, Zivadinov R, Bakshi R. Acute demyelinating optic neuritis: a review. Front Biosci 2008; 13: 2376-2390.
29. Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764-1769.
30. Rolak LA, Beck RW, Paty DW et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996; 46: 368-372.
31. Cole SR, Beck RW, Moke PS et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998; 51: 885-887.
32. Wu GF, Schwartz ED, Lei T et al. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology 2007; 69: 2128-2135.
33. Balcer LJ, Baier ML, Cohen JA et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003; 61: 1367-1373.
34. Baier ML, Cutter GR, Rudick RA et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005; 64: 992-995.
35. Beck RW: Optic neuritis. In: Miller NR and Newman NJ. Walsh and Hoyt's Clinical Neuro-ophthalmology, 5th edn (Miller NR, Newman JJ, eds). Baltimore: Williams & Wilkins 1998; pp599-647.
36. Beck RW, Trobe JD. What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology 1995; 102: 1504-1508.
37. Beck RW, Cleary PA. Recovery from severe visual loss in optic neuritis. Arch Ophthalmol 1993; 111: 300.
38. Kupersmith MJ, Gal RL, Beck RW et al. Visual function at baseline and 1 month in acute optic neuritis: Predictors of visual outcome. Neurology 2007; 69: 508-514.
39. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435-442.
40. Wenning GK, Wietholter H, Schnauder G et al. Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. Acta Neurol Scand 1994; 89: 270-273.
41. Roed HG, Langkilde A, Sellebjerg F et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-810.
42. Noseworthy JH, O'Brien PC, Petterson TM et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522.
43. Ruprecht K, Klinker E, Dintelmann T et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004; 63: 1081-1083.
44. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology 1997; 49: 1404-1413.
45. Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997; 115: 1545-1552.
46. Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999; 18: 53-63.
47. Kaufman DI, Trobe JD, Eggenberger ER et al. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 2039-2044.
48. Sellebjerg F, Nielsen HS, Frederiksen JL et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479-1484.
49. Bhatti MT; Group ONS. The final 15-year follow-up report on the neurological outcome of the Optic Neuritis Treatment Trial. 34th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), Orlando, USA, 2008.
50. Rizzo JF 3rd, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988; 38: 185-190.
51. Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120(Pt 11): 2059-2069.
52. Keltner J, Johnson C, Cello K et al. A 15-year summary of abnormal visual fields in the Optic Neuritis Treatment Trial. 34th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), Orlando, USA, 2008.
53. Brex PA, Ciccarelli O, O'Riordan JI et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164.
54. O'Riordan JI, Thompson AJ, Kingsley DP et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121(Pt 3): 495-503.
55. Beck RW, Arrington J, Murtagh FR et al. Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group. Arch Neurol 1993; 50: 841-846.
56. Beck RW, Smith CH, Gal RL et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004; 61: 1386-1389.
57. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
58. Dalton CM, Brex PA, Miszkiel KA et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002; 52: 47-53.
59. Revesz T. Axonal lesions in multiple sclerosis: an old story revisited. Brain 2000; 123(Pt 2): 203-204.
60. De Stefano N, Narayanan S, Francis GS et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
61. Bermel RA, Puli SR, Rudick RA et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005; 62: 1371-1376.
62. Frohman EM, Racke M, van Den Noort S. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Arch Neurol 2000; 57: 930-932.
63. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001; 132: 463-471.
64. Beck RW, Chandler DL, Cole SR et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-490.
65. Kinkel RP, Kollman C, O'Connor P et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684.
66. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-15.82
67. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.
68. Ghosh A, Kelly SP, Mathews J et al. Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England. J Neurol Neurosurg Psychiatry 2002; 72: 119-121.
69. Frederiksen JL, Sorensen TL, Sellebjerg FT. Residual symptoms and signs after untreated acute optic neuritis. A one-year follow-up. Acta Ophthalmol Scand 1997; 75: 544-547.
70. Cleary PA, Beck RW, Bourque LB et al. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol 1997; 17: 18-23; Quiz, 24-28.
71. Heron G, Thompson KJ, Dutton GN. The symptomatic Pulfrich phenomenon can be successfully managed with a coloured lens in front of the good eye - a long-term follow-up study. Eye 2007; 21: 1469-1472.